| Lennox-Gastaut Syndrome
Qudexy XR vs Epidiolex
Side-by-side clinical, coverage, and cost comparison for lennox-gastaut syndrome.Deep comparison between: Qudexy vs Epidiolex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEpidiolex has a higher rate of injection site reactions vs Qudexy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Epidiolex but not Qudexy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qudexy
Epidiolex
At A Glance
Oral
Once daily
Broad-spectrum anticonvulsant
Oral
Twice daily
Cannabinoid antiepileptic
Indications
- Seizures, Focal
- Generalized seizures
- Lennox-Gastaut syndrome
- Migraine Disorders
- Lennox-Gastaut syndrome
- Infantile Severe Myoclonic Epilepsy
- Tuberous Sclerosis
Dosing
Seizures, Focal, Generalized seizures, Lennox-Gastaut syndrome Monotherapy (adults and peds >=10 years): 400 mg orally once daily, titrated over 6 weeks from 50 mg/day; peds 2-9 years: weight-based 150-400 mg/day once daily. Adjunctive (adults): 200 to 400 mg once daily; adjunctive (peds 2-16 years): approximately 5 to 9 mg/kg once daily, not to exceed 400 mg/day.
Migraine Disorders 100 mg orally once daily for patients 12 years of age and older, titrated over 4 weeks from 25 mg/day.
Lennox-Gastaut syndrome, Infantile Severe Myoclonic Epilepsy Starting 2.5 mg/kg orally twice daily (5 mg/kg/day); increase after 1 week to maintenance 5 mg/kg twice daily (10 mg/kg/day); may increase up to maximum 10 mg/kg twice daily (20 mg/kg/day) in weekly increments based on response and tolerability.
Tuberous Sclerosis Starting 2.5 mg/kg orally twice daily (5 mg/kg/day); increase weekly by 2.5 mg/kg twice daily (5 mg/kg/day) as tolerated to recommended maintenance 12.5 mg/kg twice daily (25 mg/kg/day).
Contraindications
- History of hypersensitivity reaction to topiramate, QUDEXY XR, or any inactive ingredient
- History of hypersensitivity to cannabidiol or any excipient in EPIDIOLEX
Adverse Reactions
Most common (>=10%) Paresthesia, somnolence, dizziness, weight loss, anorexia, speech disorders/related speech problems, psychomotor slowing, nervousness, vision abnormal
Serious Acute myopia and secondary angle closure glaucoma, visual field defects, oligohydrosis and hyperthermia, metabolic acidosis, suicidal behavior and ideation, cognitive/neuropsychiatric adverse reactions, decrease in bone mineral density, negative effects on growth, DRESS/multiorgan hypersensitivity, serious skin reactions, anaphylaxis and angioedema, hyperammonemia and encephalopathy, kidney stones, hypothermia with concomitant valproic acid
Postmarketing Hepatic failure, hepatitis, pancreatitis, bullous skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), pemphigus, maculopathy, nephrocalcinosis
Most common (>=10%) Somnolence, decreased appetite, diarrhea, transaminase elevations, fatigue, malaise, asthenia, rash, insomnia, pyrexia, vomiting
Serious Hepatic injury, somnolence and sedation, suicidal behavior and ideation, hypersensitivity reactions
Pharmacology
Topiramate blocks voltage-dependent sodium channels, augments GABA-A receptor activity, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits carbonic anhydrase isozymes II and IV; the precise mechanisms underlying its anticonvulsant and preventive migraine effects are unknown.
Cannabidiol is a phytocannabinoid antiepileptic; its precise mechanisms of anticonvulsant action in humans are unknown and do not appear to involve interaction with cannabinoid receptors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qudexy
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (0/12) · Qty limit (0/12)
Epidiolex
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (0/12)
UnitedHealthcare
Qudexy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Epidiolex
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Qudexy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Epidiolex
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Qudexy.
Cost estimate not availableAssistance Fund: Epilepsy (Seizures): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
QudexyView full Qudexy profile
EpidiolexView full Epidiolex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.